News 90 Secondary Progressive MS Patients To Be Recruited To Test Novel Experimental Therapy 90 Secondary Progressive MS Patients To Be Recruited To Test Novel Experimental Therapy by Patricia Silva, PhD | August 19, 2014 Share this article: Share article via email Copy article link New Zealand and Ā Australian-based biotechnology company Innate ImmunotherapeuticsĀ recently announced that it has begun to recruit patients with Secondary Progressive Multiple Sclerosis (SPMS)Ā for its phase 2B trial of its experimental therapy MIS416. The study, which will be administered by theĀ Western Australian Neuroscience Research Institute (WANRI), was recently approved by theĀ Bellberry Human Research Ethics Committees (HREC), allowing the clinical trials to commence. The approval granted by the independent ethics review board indicates that Innate’s study complies with strict National Health and Medical Research Council (NHMRC) guidelines for clinical trials, which will allow WANRI to initiate the recruitment process immediately. As a result, the company is expecting to start dosing the first patients duringĀ the next 2-3 weeks, after performing extensive baseline measurements of their present MS related symptoms. āWe are really pleased to be leading this trial,” said Dr. Allan Kermode, aĀ clinical Professor of Neuroimmunology at WANRI.Ā “SPMS affects 30% of the MS population at any moment in time, and there are no approved long term effective treatment options for these patients.Ā We all hope that MIS416 might be the drug to address this urgent need.” For the double blinded randomizedĀ trial, the company will recruit up to 90 SPMS patients in Australia, 60 of which will be given MIS416 and the other 30 with placebo. Both of the groups will be treatedĀ once weekly for 12 months. Ā The research team aims to determine the efficacy and safety of MIS416 compared to patients treated with the placebo. [adrotate group=”4″] The biologically derived novel immune modulator MIS416 targets not only the regulatory functions, but also the defensive functions of the innate immune system, and it is the first MS drug to attack theĀ myeloid cells, which is a sub-set of innate immune cells that have only recently been recognized as important in the treatment of SPMS. Previous trials have already demonstrated that the drug improved the symptoms of 80% of patients with SPMS byĀ 30% or moreĀ in at least one measure of their MS-related symptoms. Multiple Sclerosis Research Australia (MSRA) and the United States National Multiple Sclerosis Society (US MS Society) have already expressed strong support of Innateās pursuit of an effective treatment for SPMS.Ā āAustralia has a strong cohort of world-leading MS neurologists who are highly experienced clinical trial investigators and strongly committed to supporting the development of new treatments for their patients,ā explained the CEO of MSRA, Dr. Matthew Miles. The next step is to extend the key trial sites to the Eastern States, which the company expects to start by next month. Print This Page About the Author Patricia Silva, PhD PatrĆcia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĆcia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles. Tags Innate Immunotherapeutics, MIS416, secondary progressive multiple sclerosis, SPMS
April 23, 2024 News by Mary Chapman Itās year 10 for MSAAās upcoming Improving Lives Benefit for MS
April 23, 2024 News by Margarida Maia, PhD AAN 2024: Subcutaneous Ocrevus led to nearly no relapses after year
April 22, 2024 News by Margarida Maia, PhD Viatris launches low-dose Copaxone generic formulation in Canada